Capricor Therapeutics (STU:4LN2) EV-to-Revenue : 19.76 (As of May. 22, 2025)

View and export this data going back to 2017. Start your Free Trial

What is Capricor Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Capricor Therapeutics's enterprise value is €323.14 Mil. Capricor Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was €16.36 Mil. Therefore, Capricor Therapeutics's EV-to-Revenue for today is 19.76.

The historical rank and industry rank for Capricor Therapeutics's EV-to-Revenue or its related term are showing as below:

STU:4LN2' s EV-to-Revenue Range Over the Past 10 Years
Min: -6.6 Med: 14.83 Max: 500.86
Current: 21.01

During the past 13 years, the highest EV-to-Revenue of Capricor Therapeutics was 500.86. The lowest was -6.60. And the median was 14.83.

STU:4LN2's EV-to-Revenue is ranked worse than
70.09% of 993 companies
in the Biotechnology industry
Industry Median: 7.17 vs STU:4LN2: 21.01

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-05-22), Capricor Therapeutics's stock price is €9.49. Capricor Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was €0.42. Therefore, Capricor Therapeutics's PS Ratio for today is 22.81.

Capricor Therapeutics EV-to-Revenue Historical Data

The historical data trend for Capricor Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Capricor Therapeutics EV-to-Revenue Chart

Capricor Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EV-to-Revenue

Get a 7-Day Free Trial

123.33

158.56

22.96

4.57

21.51

Capricor Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EV-to-Revenue	Get a 7-Day Free Trial															6.52	4.60	22.82	21.51	16.70

Competitive Comparison of Capricor Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Capricor Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Capricor Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Capricor Therapeutics's EV-to-Revenue falls into.

Save Embed

;

Save Embed

;

Capricor Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Capricor Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	323.144	/	16.357
	=	19.76

Capricor Therapeutics's current Enterprise Value is €323.14 Mil.
Capricor Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €16.36 Mil.

Capricor Therapeutics (STU:4LN2) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Capricor Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	9.49	/	0.416
	=	22.81

Capricor Therapeutics's share price for today is €9.49.
Capricor Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.42.

Capricor Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Capricor Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Capricor Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Capricor Therapeutics Inc (STU:4LN2) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

CAPR:USA 4LN2:Germany

Address

10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121

Website

https://www.capricor.com

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Capricor Therapeutics Headlines

No Headlines